NanoSALV Catalytic
An innovation in wound care is helping transform outcomes for patients with chronic wounds.
Chronic wounds can have a significant impact on patients, care providers, and the health care system. These wounds are often associated with pain, reduced mobility, lower quality of life, and increased health care utilization. For nurses and clinical teams, wound management can be complex and resource-intensive, particularly when wounds progress and require more advanced interventions.
The Challenge
Many wounds begin as small injuries that, if not treated effectively, can worsen over time. As wound severity increases, so do the clinical resources, materials, and time required to support healing.
To address this challenge, the Innovation Team partnered with NanoTess through their network of healthcare innovators. The team worked with Dr. Katrina DeZeeuw to implement a quality improvement initiative to evaluate NanoSALV Catalytic, a Health Canada-approved wound care technology indicated for both chronic and acute wounds.
The initiative focused on improving access to innovative wound care, supporting staff education, and assessing the potential role of NanoSALV Catalytic in enhancing wound healing across a select group of patients.
The Evaluation
A total of 22 wounds from 17 patients were included in the clinical initiative, with a median treatment duration of 75 days. Many of these wounds had seen no improvement in the 6-12 months preceding. Throughout the evaluation, clinicians assessed wound healing outcomes, patient experience, nursing usability, safety, and economic impact.
The Results
Within the course of treatment, something remarkable happened. For most patients, the complex wounds began to look- and feel- different.
Wounds treated with NanoSALV Catalytic experienced an average reduction in wound area of 26% and an average reduction in wound volume of 33%. Several wounds achieved complete closure during the evaluation period.
Clinicians also observed improvements in important quality-of-life indicators, including reductions in pain, wound exudate, and bleeding in select cases. No significant safety concerns were identified throughout the initiative.
Within the course of treatment we saw:
26%
Reduction in wound size
50%
Of patients saw 30-48% improvement
One patient's severe dressing pain stopped completely.
Looking Ahead
The findings from this project support continued use of NanoSALV Catalytic.
The evaluation also provides valuable insights to inform future decisions regarding the integration of NanoSALV Catalytic into standard wound care pathways, building on successful implementation experiences within other Canadian health systems.
